Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
2006;64(5 Pt 2):S24-33
P eptide access may vary based on national availability
The primary analysis for the trial product estimand was carried out using a mixed model for repeated measurements using a restricted maximum likelihood, with treatment and region as categorical fixed effects and baseline HbA 1c or body weight (depending on the analysis) as covariate
Documentation that mentions both conditions should direct coders to E66.2 exclusively
Most users find that 1 mg is effective while minimizing side effects
US$ 22.78
US$ 25.18
US$ 29.00
US$ 22.61
